Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar 1;30(5):489-501.
doi: 10.1101/gad.276733.115.

Mechanisms of metabolic dysfunction in cancer-associated cachexia

Michele Petruzzelli  1 , Erwin F Wagner  2
Affiliations
Review

Mechanisms of metabolic dysfunction in cancer-associated cachexia

Michele Petruzzelli et al. Genes Dev. .

Abstract

Metabolic dysfunction contributes to the clinical deterioration observed in advanced cancer patients and is characterized by weight loss, skeletal muscle wasting, and atrophy of the adipose tissue. This systemic syndrome, termed cancer-associated cachexia (CAC), is a major cause of morbidity and mortality. While once attributed solely to decreased food intake, the present description of cancer cachexia is a disorder of multiorgan energy imbalance. Here we review the molecules and pathways responsible for metabolic dysfunction in CAC and the ideas that led to the current understanding.

Keywords: cancer-associated cachexia (CAC); metabolic failure; skeletal muscle atrophy; white adipose tissue (WAT) browning.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Multilevel cancer pathophysiology at a glance. Schematic representation of the evolution of cancer from a single transformed cell to a systemic disease. At the “cell” level, the transformed cell (purple) is characterized by the presence of genome instability and mutations, sustained proliferative signaling, avoidance of growth suppressors, replicative immortality, resistance to cell death, and deregulated cellular energetics. At the “tissue” level, the proliferation of the tumor mass is associated with induction of angiogenesis, activation of invasion, promotion of inflammation, and avoidance of immune destruction—all hallmarks of cancer as described in Hanahan and Weinberg (2011). At the “organism” level, the developing cancer induces changes in distant organs, including metastasis, metabolic failure, and cancer cachexia, which is not included in the hallmarks of cancer. Cancer cells are shown in purple, “normal” cells are indicated in blue, immune cells are shown in green, and blood vessels are indicated in red. The arrow at the “cell” level points to the conversion from a normal cell to a cancer cell, whereas the arrow pointing to the “organism” depicts a growing tumor (purple).
Figure 2.
Figure 2.
Timeline of discoveries in cancer cachexia. In 1951, the first systemic manifestation of cancer was described in rats. In 1962, it was observed that injection of tumor preparations in mice was sufficient to induce fat atrophy. In 1983 and 1985, the first candidate molecules were identified. Seminal publications in 1993 and 2001 described a role for the ubiquitin pathway and myostatin in skeletal muscle atrophy. It was not until some years ago that an international consensus on the diagnostic criteria of CAC was reached. Promising results have been reported in late 2015 from the first phase III clinical trial targeting CAC with the ghrelin receptor agonist anamorelin (https://www.iaslc.org/news/results-phase-iii-trials-anamorelin-advanced-non-small-cell-lung-cancer-patients-cachexia).
Figure 3.
Figure 3.
Mechanisms and consequences of WAT browning in cancer cachexia. At the “cell” level, beige adipocytes are induced in WAT by a combination of signaling pathways, including β-adrenergic stimulation, inflammation mediated by IL-6, and the presence of parathyroid-related peptide (PTHrP); as a result, UCP1 levels and mitochondrial content are increased. At the “tissue” level, CAC is associated with the appearance of islets of beige adipocytes in WAT, surrounded by white adipocytes of reduced size due to ongoing lipolysis. WAT browning and lipolysis result in decreased energy storage and increased production of heat. In the context of obesity, WAT browning is beneficial, while in cancer patients, it is detrimental.
Figure 4.
Figure 4.
Conceptual evolution of the understanding of cancer cachexia. The scheme depicts the way we envision multifactorial cancer cachexia in 2015, involving reciprocal compounding interactions between the tumor and the organism, which result in inflammatory and metabolic changes distant from the pathological sites of tumor growth. This way is very different from the unidirectional way that “cancer aggression” was viewed decades ago (Costa 1977).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S, Guttridge DC. 2004. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 114: 370–378. - PMC - PubMed
    1. Agustsson T, D'Souza MA, Nowak G, Isaksson B. 2011. Mechanisms for skeletal muscle insulin resistance in patients with pancreatic ductal adenocarcinoma. Nutrition 27: 796–801. - PubMed
    1. Anker SD, Coats AJ. 1999. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest 115: 836–847. - PubMed
    1. Argiles JM, Lopez-Soriano FJ. 1999. The role of cytokines in cancer cachexia. Med Res Rev 19: 223–248. - PubMed
    1. Arruda AP, Milanski M, Romanatto T, Solon C, Coope A, Alberici LC, Festuccia WT, Hirabara SM, Ropelle E, Curi R, et al. 2010. Hypothalamic actions of tumor necrosis factor α provide the thermogenic core for the wastage syndrome in cachexia. Endocrinology 151: 683–694. - PubMed

Publication types

MeSH terms

-